10 August 2018
Visiongain has launched a new pharma report Global Treatment for Neglected Tropical Disease Market 2017-2027: Malaria, Dengue, Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease
According to the Centers for Disease Control and Prevention (CDC), one hundred percent of low-income countries are affected by at least five neglected tropical diseases simultaneously. Worldwide, 149 countries and territories are affected by at least one neglected tropical disease (NTD). The disease burden, however, is not restricted to these areas since vectors and parasites can often spread to other regions via travellers or cargo. Every year, malaria alone results in one to three million deaths out of approximately half a billion cases, while many more go undetected or undiagnosed.
The lead analyst of the report commented “The treatment for neglected tropical disease market is set to experience considerable growth over the next decade. The main growth drivers include, rising awareness towards neglected tropical disease, increasing prevalence of neglected disease such as malaria and dengue as well as increasing governments’ initiatives.
There are still gaps that need to be met. Improved diagnostics for neglected tropical diseases for example, are essential for guiding treatment strategies at different thresholds of control, interruption of transmission, elimination and post-elimination surveillance.”
Leading companies featured in the report include Pfizer, Inc., Bayer, GlaxoSmithKline plc, Merck & Co., Inc., Novartis International AG, Takeda Pharmaceutical Company Ltd, Sanofi S.A. and Eisai Co., Ltd.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
11 October 2021
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
07 October 2021
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
06 October 2021
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market